Merseyside and Cheshire Cancer Registry produced a skin cancer bulletin to raise awareness as part of the Health of the Nation activity.' The media focused on the reported local excess of 17% (standardised registration ratio = 117 for 1987-91 compared with England and Wales; 95% confidence interval, 114, 119),' and an increasing age standardised incidence rate for skin cancer over the 1970s and 1980s. The excess was difficult to interpret, partly because the national reference is influenced by anecdotally known variations in registration practice-ie those lesions that registries intend to register. The English skin cancer target-"to halt the year-on-year increase in the incidence of skin cancer by 2005 
Results

All registries responded (table 1). Only 3/11
English and 2/7 other UK registries registered every lesion (ie including "multiples") from the four categories, and there was considerable inter-registry and inter-category variation. The commonest practice for basal cell carcinoma (11/18) was effectively to register the "first only" in any individual. Registration practice elsewhere in the UK was slightly more uniform for the other three cancer categories than in England. Only 7/11 English and 1/7 other registries recorded Breslow thickness and Clark's level to stage cutaneous malignant melanoma-the rest recorded neither.
Discussion
This study was time consuming but showed substantial nationwide variations in registration practice. Such variations were unhelpful in interpreting the Merseyside and Cheshire excess of skin cancer to local media, although the excess mortality for males with non-melanoma skin cancer implied a real increase in incidence. Despite being important indicators of quality assurance in skin cancer registration, case ascertainment, timeliness, record completeness, and the validity of "registrations" are irrelevant for cancers that registries do not attempt to record.
Basal cell carcinoma is often multiple,3 providing an extreme example of the problems with registering all "multiple" neoplasms. Basal cell carcinoma is also the commonest skin cancer (eg locally, "first" basal cell carcinomas account for approximately three quarters of skin cancer'). As expected, perhaps, but previously undocumented systematically, basal cell carcinoma registration is sufficiently variable to distort target setting and monitoring. Although the Scottish, Welsh, and Northern Irish health strategies do not contain an English-style skin cancer target,3 variable registration practices complicate comparisons with England.
Cynically, an impressive reduction in skin cancer incidence could follow if all English registries copied the minority-not registering basal cell carcinoma at all! Arguably, the workload is unwarranted for the favourable prognosis and likely data quality problems involved. Consensus about, for example, whether someone with three basal cell carcinomas is counted once ("person based") or thrice ("tumour episode based") would reduce the variable regional input into the national dataset thereby improving incidence accuracy and target setting. Person based and episode based data have their merits. These are informing prevention and measuring service use respectively. Furthermore, a standard approach to skin cancer registration would allow best use of scarce registration resources. Concern about worldwide variation in non-melanoma skin cancer registration practice has led to "total cancer incidence" being published including and excluding such cases, illustrating that this problem extends beyond the UK.5
The model core contract for cancer registries could have clarified this registration problem, but apparently excludes non-melanoma skin cancer from the required dataset.6 For cutaneous malignant melanoma, recording stage has yet to become universal.
Appropriately, much effort is directed at skin cancer prevention. The problems lie in target setting and monitoring. A person based skin cancer target, or one excluding non-melanoma skin cancer, could rationalise monitoring, but would ignore the personal and health care consequences for affected people. An option appraisal, of the costs and consequences of skin cancer registration, is therefore recommended to ensure that decisions about practice become evidence based.
